These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24114694)

  • 21. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
    Boyce AM
    Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H; Ishihara S; Toda Y; Oda Y
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RANK signalling in bone lesions with osteoclast-like giant cells.
    Won KY; Kalil RK; Kim YW; Park YK
    Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
    Rosario M; Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Higuchi T; Abe K; Taniguchi Y; Aiba H; Tanzawa Y; Murakami H; Tsuchiya H
    Anticancer Res; 2017 Feb; 37(2):749-754. PubMed ID: 28179326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
    Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
    Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Narlumosbart: First Approval.
    Dhillon S
    Drugs; 2024 Jan; 84(1):105-109. PubMed ID: 38112898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
    Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
    Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
    Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
    Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
    Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
    Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
    Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
    BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Giant Cell Tumor of Bone: An Update.
    Basu Mallick A; Chawla SP
    Curr Oncol Rep; 2021 Mar; 23(5):51. PubMed ID: 33754215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
    BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Giant cell tumour of bone in the denosumab era.
    van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting RANKL in breast cancer: bone metastasis and beyond.
    Azim H; Azim HA
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
    Gossai N; Hilgers MV; Polgreen LE; Greengard EG
    Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RANKL inhibition in the treatment of bone metastases.
    Lipton A; Jun S
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early evaluation of the therapeutic effect of denosumab on tartrate-resistant acid phosphatase 5b expression in a giant cell tumor of bone: a case report.
    Watanabe N; Matsumoto S; Shimoji T; Ae K; Tanizawa T; Gokita T; Motoi N; Ueno T; Koizumi M
    BMC Res Notes; 2014 Sep; 7():608. PubMed ID: 25193435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
    Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
    Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
    Cowan RW; Singh G; Ghert M
    J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.